Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

CRISPR Therapeutics AG (CRSP)

52.78   2.31 (4.58%) 01-27 16:00
Open: 50.16 Pre. Close: 50.47
High: 53.17 Low: 50.02
Volume: 866,500 Market Cap: 4,132(M)

Technical analysis

as of: 2023-01-27 4:43:34 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 63.28     One year: 73.91
Support: Support1: 44.76    Support2: 38.93
Resistance: Resistance1: 54.18    Resistance2: 63.28
Pivot: 49.79
Moving Average: MA(5): 51.45     MA(20): 48.06
MA(100): 54.93     MA(250): 60.6
MACD: MACD(12,26): 0.9     Signal(9): 0.3
Stochastic oscillator: %K(14,3): 72.1     %D(3): 74.7
RSI: RSI(14): 60.1
52-week: High: 86.94  Low: 38.93
Average Vol(K): 3-Month: 1,070 (K)  10-Days: 1,000 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ CRSP ] has closed below upper band by 8.0%. Bollinger Bands are 42.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 53.2 - 53.46 53.46 - 53.72
Low: 49.43 - 49.69 49.69 - 49.95
Close: 52.34 - 52.77 52.77 - 53.21

Company Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Headline News

Thu, 26 Jan 2023
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains ... - Nasdaq

Thu, 26 Jan 2023
Interesting CRSP Put And Call Options For March 10th - Nasdaq

Wed, 25 Jan 2023
3 Gene Editing Stocks to Buy Now OR You'll Be Kicking Yourself Later - InvestorsObserver

Mon, 23 Jan 2023
Hussman Strategic Advisors Inc. sells 10,400 CRISPR Therapeutics ... - Best Stocks

Sun, 22 Jan 2023
Rockefeller Capital Management L.P. Raises Position in CRISPR ... - MarketBeat

Fri, 20 Jan 2023
Should Vanguard Growth ETF (VUG) Be on Your Investing Radar? - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 78 (M)
% Held by Insiders 7.707e+007 (%)
% Held by Institutions 1.4 (%)
Shares Short 11,640 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -6.6273e+008
EPS Est Next Qtl -0.75
EPS Est This Year -2.44
EPS Est Next Year -3.02
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -4
Return on Assets (ttm) 877.7
Return on Equity (ttm) -16.7
Qtrly Rev. Growth 1.409e+007
Gross Profit (p.s.) -55.38
Sales Per Share -19.05
EBITDA (p.s.) 2.97706e+008
Qtrly Earnings Growth 3.7
Operating Cash Flow 0 (M)
Levered Free Cash Flow -468 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -2.78
Price to Cash Flow 3.38

Stock Dividends

Dividend 0
Forward Dividend 9.34e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.